




RealRate

PHARMACEUTICAL 2012

International Stem Cell CORP
Rank 192 of 196



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest weakness of International Stem Cell CORP is the variable Assets, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.0038%, being 234% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	3,019
Cost of Goods Sold	3,334
Intangible Assets	1,282
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	16
Other Compr. Net Income	0
Other Expenses	3,881
Other Liabilities	2,114
Other Net Income	-3,490
Other Revenues	7,766
Property and Equipment	1,420
Research and Development	18,294
Selling, General and Administrative Expense	31,684

Output Variable	Value in 1000 USD
Assets	5,737
Liabilities	2,114
Expenses	57,193
Revenues	7,766
Stockholders Equity	3,623
Net Income	-52,917
Comprehensive Net Income	-52,917
BaseVar	38,150
ECR before LimitedLiability	-1,147%
Economic Capital Ratio	0.0038%